X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (30) 30
hygiene (30) 30
medical or veterinary science (30) 30
preparations for medical, dental, or toilet purposes (30) 30
chemistry (24) 24
metallurgy (24) 24
organic chemistry (24) 24
peptides (24) 24
humans (12) 12
index medicus (10) 10
specific therapeutic activity of chemical compounds ormedicinal preparations (10) 10
oncology (9) 9
aged (8) 8
female (8) 8
middle aged (8) 8
adult (7) 7
male (7) 7
aged, 80 and over (6) 6
antibodies, monoclonal - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
heterocyclic compounds (6) 6
neoplasm staging (6) 6
treatment outcome (6) 6
antibodies, monoclonal - adverse effects (5) 5
colorectal neoplasms - drug therapy (5) 5
proto-oncogene proteins - genetics (5) 5
proto-oncogene proteins p21 (5) 5
ras proteins - genetics (5) 5
antibodies, monoclonal - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
colorectal neoplasms - metabolism (4) 4
colorectal neoplasms - pathology (4) 4
disease-free survival (4) 4
antineoplastic agents - therapeutic use (3) 3
colorectal neoplasms - mortality (3) 3
drug administration schedule (3) 3
infusions, intravenous (3) 3
investigating or analysing materials by determining theirchemical or physical properties (3) 3
kras (3) 3
measuring (3) 3
mutation (3) 3
physics (3) 3
predictive value of tests (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
testing (3) 3
therapy (3) 3
young adult (3) 3
activation (2) 2
adenocarcinoma - drug therapy (2) 2
amg 479 (2) 2
antibodies, monoclonal - pharmacokinetics (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
biochemistry & molecular biology (2) 2
biomarkers, tumor - genetics (2) 2
cancer (2) 2
cell biology (2) 2
cells (2) 2
cetuximab (2) 2
cetuximab plus irinotecan (2) 2
chemotherapy (2) 2
chemotherapy, adjuvant (2) 2
colorectal neoplasms - genetics (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
fluorouracil - administration & dosage (2) 2
fluorouracil - adverse effects (2) 2
gene expression regulation, neoplastic (2) 2
growth-factor receptor (2) 2
herpesvirus 1, human (2) 2
immunology (2) 2
insulin (2) 2
kaplan-meier estimate (2) 2
leucovorin - administration & dosage (2) 2
leucovorin - adverse effects (2) 2
melanoma - drug therapy (2) 2
microbiology (2) 2
oncolytic viruses (2) 2
open-label (2) 2
pancreatic neoplasms - drug therapy (2) 2
pancreatic neoplasms - pathology (2) 2
pembrolizumab (2) 2
plus (2) 2
prognosis (2) 2
prospective studies (2) 2
receptor, igf type 1 - immunology (2) 2
skin neoplasms - drug therapy (2) 2
skin neoplasms - pathology (2) 2
survival (2) 2
survival analysis (2) 2
1st-line treatment (1) 1
acquired-resistance (1) 1
adaptive immune resistance (1) 1
adenocarcinoma - blood (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - pathology (1) 1
adenocarcinoma - secondary (1) 1
adjuvants, immunologic - administration & dosage (1) 1
adjuvants, immunologic - adverse effects (1) 1
adjuvants, immunologic - metabolism (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (46) 46
French (12) 12
Chinese (3) 3
German (3) 3
Portuguese (2) 2
Korean (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 3, pp. 228 - 235
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4697 - 4705
Purpose Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved... 
KRAS MUTATIONS | MCRC | ONCOLOGY | STATISTICS | CETUXIMAB PLUS IRINOTECAN | CHEMOTHERAPY CT | OPEN-LABEL | COMBINATION | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Colorectal Neoplasms - mortality | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4706 - 4713
Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in... 
SURVIVAL | 1ST-LINE TREATMENT | CONTROLLED-TRIAL | SUPPORTIVE CARE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | KRAS | OXALIPLATIN | FAILURE | CHEMOTHERAPY | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 25, pp. 2780 - 2788
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2013, Volume 19, Issue 15, pp. 4282 - 4289
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2014, Volume 44, Issue 5, pp. 442 - 447
Journal Article
Cancer Research, ISSN 0008-5472, 10/2014, Volume 74, Issue 19 Supplement, pp. 3683 - 3683
Journal Article
The Journal of Immunology, ISSN 0022-1767, 03/2003, Volume 170, Issue 6, pp. 3154 - 3161
Journal Article
Blood, ISSN 0006-4971, 11/2004, Volume 104, Issue 11, pp. 5054 - 5054
Abstract Allogeneic hematopoietic transplantation following nonmyeloablative preparative conditioning (also know as “mini-dose transplantation”) is frequently... 
Journal Article
05/2019
Methods and compositions for treating primary hepatic cancers and/or secondary hepatic cancers using a combination of talimogene laherparepvec and... 
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS | HYGIENE | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | MEDICAL OR VETERINARY SCIENCE | HUMAN NECESSITIES
Patent
10/2019
Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab... 
TESTING | HYGIENE | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES | MEDICAL OR VETERINARY SCIENCE | MEASURING | PHYSICS | HUMAN NECESSITIES
Patent